Cells communicate with their environment, in part, through cell surface receptors. Engineering receptors that both sense arbitrary inputs and provide outputs orthogonal to endogenous signaling pathways has been a challenge. Now, Lim and colleagues report a system based on synthetic Notch receptors that allows independent control of both inputs and outputs in diverse cell types.
Altering a cell's ability to perceive and respond to extracellular signals through genetic engineering has historically been an important strategy for dissecting the biology of cell surface receptors and intracellular signaling pathways. Important insights can often be achieved by minimalist point mutations that disable or modify receptor (or associated downstream signaling component) functions. However, the introduction of de novo synthetic receptors linked to signaling pathways orthogonal to other signaling chains within the cell could open up new possibilities for understanding how cells communicate with their environment and for generating powerful new treatments for disease based on engineered therapeutic cells.
In two companion papers in this issue of Cell, Lim and colleagues take a major step toward this goal, introducing a novel platform for engineering multiple orthogonal receptor-to-transcription pathways in cells and demonstrating its potential for engineering enhanced functionality in the setting of a clinically promising cell therapy, adoptive T cell transfer in cancer . In Morsut et al., the team develop synthetic Notch receptors as a platform for combining arbitrary extracellular ligand recognition with a variety of intracellular transcriptional outputs. Several features made Notch attractive for this goal. First, Notch has a well-defined modular structure, comprised of the extracellular epidermal growth factor repeat ligand-binding domain, the transmembrane ''core'' domain, and the cleavable intracellular domain. This modular nature facilitated exchange of the ligandbinding and intracellular domains for novel synthetic domains. Second, Notch normally signals directly to the nucleus without other signaling intermediates: engagement of native Notch with its physiological ligand Delta leads to an A disintegrin and metalloproteinase (ADAM)-mediated cleavage event within the core domain, releasing its intracellular domain that directly traffics to the nucleus to act as a transcription factor. Thus, Notch is intrinsically capable of acting independently of other intracellular signaling pathways, without relying on ubiquitous kinases that have roles in multiple signaling chains in the cell. Prior studies demonstrated that Notch is particularly amenable to modification; both the extracellular ligand-binding domain and intracellular transcriptionregulating domains had been separately exchanged for novel binding domains or reporter domains, respectively (Gordon et al., 2015; Lecourtois and Schweisguth, 1998; Struhl and Adachi, 1998) . Morsut et al. show that the epidermal growth factor repeat ligand-binding domain can be replaced by a number of different ligand-binding domains, including single-chain antibodies, nanobodies, or polypeptide tags, to allow the synthetic receptor to recognize diverse alternative ligands (Figure 1 ). In parallel, they replace the native intracellular domain with one of several different artificial transcription factor domains, imparting the capacity for the engineered receptor to induce targeted transcription orthogonal to other signaling pathways in the cell. In this panel of engineered synthetic Notchs (synNotchs), receptors are also orthogonal to one another, and the authors demonstrate that pairs of synthetic receptors can be introduced into the same cell to provide combinatorial responses to multiple extracellular cues. Similar to native Notch-Delta interactions, synNotch receptors do not respond to soluble ligands, but are instead triggered by surface-immobilized ligand or ligands expressed by neighboring cells, providing cell contact-dependent signaling (Figure 1) . Cell contact-dependent signaling enabled Morsut et al. to demonstrate spatially patterned signaling among multiple cell types, where recognition of target ligand-expressing cells at one location in cell culture induces only neighboring synNotch cells to express a reporter protein, mimicking one of the natural features of the Delta-Notch system in development. The synthetic receptors function in fibroblasts, lymphocytes, and primary neurons, suggesting that diverse cell types contain the required proteolytic machinery for ligand-induced release of the synNotch intracellular domains.
In the companion paper, Roybal et al. apply this powerful new platform to the problem of controlling the activity of engineered T cells for adoptive cell therapy of cancer (Rosenberg and Restifo, 2015) . Recent clinical trials treating leukemia patients with chimeric antigen receptor (CAR) T cells (T cells transduced with a synthetic receptor combining an antibody-like domain to the intracellular signaling machinery of the T cell receptor) have demonstrated that engineered T cells can produce spectacular longlasting remissions in a majority of patients with certain forms of advanced leukemias (Brentjens et al., 2013; Maude et al., 2014) . However, these trials have focused on the use of CARs that target T cells against leukemias expressing a unique cell surface protein (CD19), which among normal tissues is shared only by B cells. Infusion of these CD19-targeted CAR T cells leads to elimination of both the tumor cells and normal B cells, but the latter side effect can be safely managed in the clinic. Most cancers do not express unique cell surface proteins that can be safely targeted in this way, and a major hurdle for expanding this approach more broadly in cancer immunotherapy is determining how to enable T cells to identify tumor cells without attacking healthy tissues that might express some of the same surface markers (Klebanoff et al., 2016) .
Roybal et al. use the synNotch system to engineer T cells with a two-step logic gate controlling induction of their effector functions, such that cells are only targeted by the T cell if they express two different identifying ligands. This is achieved by introducing a synNotch receptor whose activation by binding to a ligand A triggers expression of a CAR that recognizes a second ligand B; only cells expressing both A and B will trigger T cell activation (e.g., target cell lysis or cytokine production). The authors demonstrate good fidelity of this system, with no activation of T cells that encounter target cells expressing only one of the two ligands and with rapid induction of CAR expression within a few hours when T cells are exposed to targets bearing both ligands. Importantly, the dual-receptor T cells also downregulate CAR expression when the ligands are removed within 24 hr, which may be important to prevent activated cells from being triggered by single-ligand-expressing tissues outside of the tumor microenvironment. Roybal et al. go on to demonstrate that these synNotch/CAR dual-receptor T cells effectively attack tumors expressing both target ligands in vivo in a humanized mouse model, without eliminating single-ligand-expressing tumors.
While the synNotch platform developed in these studies provides a compelling new addition to the synthetic biology toolkit in mammalian systems, there are also some limitations identified by the authors. The release of a transcription factor directly from the engaged receptor provides a convenient means to engineer transcription insulated from other signaling pathways in the cell, but this approach means signaling is stoichiometric, with one engaged receptor leading to (presumably) one activated transcription factor molecule-unlike many intracellular signaling chains where enzymatic cascades produce great amplification of the initiating signal. The synNotch receptors are also confined (like their native Notch counterparts) to responding to surface-or cell-membrane-localized ligands, at least in their current configuration. However, even with these caveats, the great breadth of possibilities opened up by this platform for both basic cell biology and enhancement of cell therapies represent an exciting step forward for the field of synthetic biology in human cells.
